Dermatology Medical News about psoriasis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Biologics in the management of psoriasis
Clinical, Cosmetic and Investigational Dermatology, 07/23/09

Bahner JD et al. – Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor–alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT–874 target interleukin–12 and interleukin–23, and they have demonstrated efficacy in the treatment of psoriasis.

<< Previous
Economy forces Most Wired hospitals to limit IT spending

Next >>
Cutaneous melanoma - atypical variants and presentations